Nature Reviews Rheumatology

Article	Citations
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors	539
Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes	387
Translating IL-6 biology into effective treatments	352
Autoimmune and inflammatory diseases following COVID-19	280
Mechanisms and therapeutic implications of cellular senescence in osteoarthritis	275
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment	268
Synovial inflammation in osteoarthritis progression	232
Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines	226
Global epidemiology of systemic lupus erythematosus	221
Emerging pharmaceutical therapies for osteoarthritis	202
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications	186
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	183
Systemic and organ-specific immune-related manifestations of COVID-19	181
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	172
IgG4-related disease: an update on pathophysiology and implications for clinical care	161
The gut–joint axis in rheumatoid arthritis	155
New insights into the role of antinuclear antibodies in systemic lupus erythematosus	139
COVID-19 revisiting inflammatory pathways of arthritis	137
Toll-like receptor signalling in B cells during systemic lupus erythematosus	137
Kawasaki disease: pathophysiology and insights from mouse models	135
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?	126
Immune-mediated necrotizing myopathy: clinical features and pathogenesis	126
Early-stage symptomatic osteoarthritis of the knee — time for action	125
A new immunometabolic perspective of intervertebral disc degeneration	122
Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison	122

Cell-based strategies for IVD repair: clinical progress and translational obstacles	118
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	118
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis	116
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis	114
Combating physical inactivity during the COVID-19 pandemic	112
Rheumatic disease and COVID-19: epidemiology and outcomes	111
Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis	109
Global epidemiology of vasculitis	108
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis	103
Digital health technologies: opportunities and challenges in rheumatology	103
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	102
The non-coding RNA interactome in joint health and disease	100
Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis	97
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	93
Interplay between genetics and epigenetics in osteoarthritis	88
Oral surveillance and JAK inhibitor safety: the theory of relativity	87
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases	83
PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets	77
Fibroblast growth factor signalling in osteoarthritis and cartilage repair	76
Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response	75
Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease	73
TNF in the era of immune checkpoint inhibitors: friend or foe?	72
Immune cartography of macrophage activation syndrome in the COVID-19 era	72
Axial spondyloarthritis: concept, construct, classification and implications for therapy	71
The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic	71
The evolution of nerve growth factor inhibition in clinical medicine	69
Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy	69
Sex steroids and autoimmune rheumatic diseases: state of the art	64
The endothelium–bone axis in development, homeostasis and bone and joint disease	64
Current and future therapies for primary Sjögren syndrome	63
Location, location, location: how the tissue microenvironment affects inflammation in RA	62
Interleukin-2 and regulatory T cells in rheumatic diseases	58
Targeting interferon-γ in hyperinflammation: opportunities and challenges	55
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation	55
Treatment of axial spondyloarthritis: an update	55
Transforming clinical trials in rheumatology: towards patient-centric precision medicine	54
Cardiovascular effects of approved drugs for rheumatoid arthritis	54
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research	54
Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica	53
Global epidemiology of rheumatoid arthritis	52
Biological classification of childhood arthritis: roadmap to a molecular nomenclature	52
Insights into the biology and therapeutic implications of TNF and regulatory T cells	51
Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential	49
MIS-C: early lessons from immune profiling	49
Why remission is not enough: underlying disease mechanisms in RA that prevent cure	48
Psoriatic arthritis from a mechanistic perspective	47
Clinical value of DNA methylation markers in autoimmune rheumatic diseases	47
Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission	47
Lyme arthritis: linking infection, inflammation and autoimmunity	47
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	44

Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care	43
The decisive early phase of bone regeneration	42
Detection of microvascular changes in systemic sclerosis and other rheumatic diseases	41
The role of HIF proteins in maintaining the metabolic health of the intervertebral disc	41
Interferon lambda in inflammation and autoimmune rheumatic diseases	40
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases	39
Immunogenicity of biologic agents in rheumatology	39
Erosive hand osteoarthritis: latest findings and outlook	39
Core and adjunctive interventions for osteoarthritis: efficacy and models for implementation	38
Disorders of ubiquitylation: unchained inflammation	36
Key opinion leaders — a critical perspective	35
Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities	35
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases	35
An introduction to machine learning and analysis of its use in rheumatic diseases	35
Applying precision medicine to unmet clinical needs in psoriatic disease	34
Biomarker development for axial spondyloarthritis	33
Hypertension meets osteoarthritis — revisiting the vascular aetiology hypothesis	33
From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis	32
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	32
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms	32
Mechanisms and clinical implications of intervertebral disc calcification	31
The role of neutrophils in rheumatic disease-associated vascular inflammation	31
Vascular Behçet syndrome: from pathogenesis to treatment	30
Cartilage calcification in osteoarthritis: mechanisms and clinical relevance	28
Inflammation and DNA damage: cause, effect or both	27
Rheumatic diseases in Africa	27
Acute exacerbation of interstitial lung disease associated with rheumatic disease	26
Importance of lymphocyte–stromal cell interactions in autoimmune and inflammatory rheumatic diseases	26
How COVID-19 is changing rheumatology clinical practice	25
Immunological memory in rheumatic inflammation — a roadblock to tolerance induction	25
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	24
Joint-on-chip platforms: entering a new era of in vitro models for arthritis	24
The role of mitochondria in rheumatic diseases	23
Studying osteoarthritis with artificial intelligence applied to magnetic resonance imaging	23
Sex- and gender-related differences in psoriatic arthritis	23
Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases	22
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study	22
Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management	22
Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases	22
Adopting PROs in virtual and outpatient management of RA	22
Treat-to-target in axial spondyloarthritis — what about physical function and activity?	21
Differentiating between UCTD and early-stage SLE: from definitions to clinical approach	20
High risk of autoimmune diseases after COVID-19	20
Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia	20
Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies	20
State-of-the-art evidence in the treatment of systemic sclerosis	20
Challenges in the management of older patients with inflammatory rheumatic diseases	19
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	19
Glycobiology of rheumatic diseases	19
Intervertebral disc degeneration and osteoarthritis: a common molecular disease spectrum	18
Regulation of activated T cell survival in rheumatic autoimmune diseases	18
Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis	18
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	17
Matrix metalloproteinases in arthritis: towards precision medicine	17
Treatment of lupus nephritis: consensus, evidence and perspectives	17
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need	17
Emerging concepts of type I interferons in SLE pathogenesis and therapy	17
Disease stratification in GCA and PMR: state of the art and future perspectives	17
Endothelial function and endothelial progenitor cells in systemic lupus erythematosus	17
Machine learning in precision medicine: lessons to learn	16
Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis	16
Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies	15
Precision medicine: the precision gap in rheumatic disease	15
Targeting calcium-related mechanotransduction in early OA	14
New insights into the treatment of CTD-ILD	13
JAK inhibitors and VTE risk: how concerned should we be?	12
Precision medicine in systemic lupus erythematosus	12
Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management	12
Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease	11
Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19	11
Assessment of disease outcome measures in systemic sclerosis	10
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis	10
Busting the myth of methotrexate chronic hepatotoxicity	10
Mapping the musculoskeletal system one cell at a time	10
Evolving concepts in systemic lupus erythematosus damage assessment	10
Age-related mechanisms in the context of rheumatic disease	9
Revisiting the cardiovascular risk of hydroxychloroquine in RA	9
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy	9
Genome editing to define the function of risk loci and variants in rheumatic disease	9
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	9

TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond	9
Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care	9
Striking a balance in rheumatoid arthritis prevention trials	8
New insights into RA genetics from GWAS meta-analysis	8
The road to equity for women in academic rheumatology	8
Spectrum and impact of checkpoint inhibitor-induced irAEs	8
The Musculoskeletal Knowledge Portal: improving access to multi-omics data	7
Skin–kidney crosstalk in SLE	7
Does psoriasis treatment affect PsA development?	7
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	7
Critical appraisal of serum urate targets in the management of gout	7
Osteocyte death promotes bone loss	6
Synovial macrophage populations linked to RA remission	6
The (Orf)ull truth about IRF5 and type I interferons in SLE	6
The bone marrow side of axial spondyloarthritis	6
Linking cell mechanobiology and inflammation in IVD degeneration	6
NETs directly injure cartilage in RA	6
IL-37 linked to gout pathogenesis and treatment	5
New refinements aim to optimize articular cartilage tissue engineering	5
Publisher Correction: Global epidemiology of systemic lupus erythematosus	5
Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells	5
TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out	5
Hydroxychloroquine dose: balancing toxicity and SLE flare risk	5
Kawasaki disease and MIS-C share a host immune response	5
Voclosporin improves outcomes in lupus nephritis	5
Targeted delivery of immunosuppressant in SLE	5
Somatic mutations cause VEXAS syndrome	5
JAK inhibitors: new indication and emerging safety data in 2022	5
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	5
β-carotene blocks the inflammasome	5
HIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis	5
T cells in SSc skin lesions: knowing your enemy	5
A path towards personalized medicine for autoinflammatory and related diseases	4
Linking NAD metabolism and DNA repair to inflammation in SSc	4
Epidemiology of Sjögren syndrome	4
Exercise exerts anti-inflammatory effects on muscle via the JAK–STAT pathway	4
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	4
Can machine learning unravel the complex IIM spectrum?	4
How does age determine the development of human immune-mediated arthritis?	4
Removing barriers and disparities in health: lessons from the COVID-19 pandemic	4
Disease onset goes with its gut in RA	4
PDGF-BB is the key to unlocking pathological angiogenesis in OA	4
2021 ACR guideline reflects changes in RA treatment	4
Telemedicine: a solution for everyone?	4
MIS-C: myths have been debunked, but mysteries remain	4
IL-33 is a potential new target in OA	4
SUMOylation links metabolic and aggressive phenotype of RA FLS	4
Progress continues in prediction of the response to treatment of RA	4
Cross-trial comparisons in reviews: proceed with caution	4
Combining TNF blockade with immune checkpoint inhibitors in patients with cancer	4
Effect of DMARDs on the immunogenicity of vaccines	4
A comprehensive guide for managing the reproductive health of patients with vasculitis	4
Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	4
COVID-19 vaccination in individuals with inflammatory rheumatic diseases	4
Targeting FLS signalling in RA	4
Synovial fibroblast expansion in RA is driven by Notch signalling	4
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies	4
Innate immune memory in inflammatory arthritis	4
Combination therapy for septic arthritis	4
How do dietary interventions affect serum urate and gout?	3
Pain in OA: is cartilage loss a major contributor?	3
Down syndrome: insights into autoimmune mechanisms	3
Can we implement the new research agenda for mental health?	3
Safety and efficacy of HSCT for systemic sclerosis across clinical trials	3
Synthetic Wnt agonists rapidly rebuild bone in vivo	3
GCA management guidelines — vive la différence?	3
Switching on resolution to treat RA moves closer to reality	3
Gut microbiome could predict drug response in RA	3
How well do the new classification criteria for SLE perform?	3
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	3
Cardio-rheumatology: it’s time to collaborate	3
Ageing stem cells hold the key to age-related bone degeneration	3
Opioid and Hedgehog signalling pathways converge to modulate OA	3
Targeting senescence in OA	3
NETs revealed as source of carbamylated proteins in RA	3
Optimizing methotrexate withdrawal during COVID vaccination	3
Publisher Correction: Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis	3
Pathogenic role for MIF likely in SpA	3
IL-17 sustains plasma cells in SLE	3
Genetic risk scores in inflammatory arthritis: a new era?	3
Keeping immunostimulatory self-RNA under the rADAR	3
Mechanisms and rationale for uricase use in patients with gout	3
In silico tools predict effects of drugs on bone remodelling	3
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce	3
JAK inhibitors boost bone formation	3
What could a new disease activity score for polymyalgia rheumatica do better?	3
New data emerging on outcomes for patients with COVID-19 and rheumatic diseases	3
Targeting the CCR6–CCL20 axis improves experimental PsA	3
Targeting articular Mmp13 in OA	2
Kindlin-2 reduces IVD inflammation	2
Targeting IL-1β expression in IVDD	2
Discontinuing methotrexate to enhance vaccine response	2
Induced Treg cells stay on course	2
CAR T cells induce remission in a patient with refractory SLE	2
Learning from similarities between vaccine responses and SLE	2